A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma

Recruitment & Eligibility

Status: ot Recruiting

Sex: Female

Target Recruitment: 140

Inclusion Criteria

•Patient is a female = 18 years at the day of consenting to the study
•Patient has a histologically confirmed diagnosis of advanced endometrial carcinoma with available tissue specimen, either archival tissue (one block or a minimum of 20 unstained slides) or fresh formalin fixed tumor biopsy, for identification of PI3K pathway activation
•Patient has experienced objective progression of disease on or after first-line anti-neoplastic treatment for advanced or metastatic endometrial carcinoma
•Patient has recovered (to grade = 1) from all clinically significant toxicities related to prior antineoplastic therapies (with the exception of alopecia) and has adequate bone marrow and organ functions
•Patient has at least one measurable lesion as per RECIST
•Patient has an Eastern Cooperative Oncology Group (ECOG) performance status = 2 which is not declining during the last 2 weeks before the signature of the main study Informed Consent Form (S-ICF).

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1.Patient has received previous treatment with PI3K and/or mTOR inhibitors
2.Patient has received more than one line of antineoplastic treatment for advanced or metastatic disease (for definition of prior lines of therapy please refer to inclusion criterion 4)
3.Patient has active uncontrolled or symptomatic CNS metastases
4.Note: Patients with controlled and asymptomatic CNS metastases may participate in this trial. As such, the patient must have completed any prior treatment for CNS metastases > 28 days (including radiotherapy and/or surgery) prior to enrollment in this study and should not be receiving chronic corticosteroid therapy for the CNS metastases.
5.Patient has a concurrent malignancy or has had a malignancy in the last 3 years prior to start of study treatment (with the exception of adequately treated basal or squamous cell carcinoma or cervical carcinoma in situ)
6.Patient has received pelvic and/or para-aortic radiotherapy = 28 days or limited filed palliative radiotherapy = 14 days prior to enrollment in this study or has not recovered from side effects of such therapy at the time of initiation of screening procedures.
7.Patient has had major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery
8.Patient has active cardiac disease including any of the following:
•Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
•QTc > 480 msec on screening ECG (using the QTcF formula)
•Unstable angina pectoris
•Ventricular arrhythmias except for benign premature ventricular contractions
•Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication
•Conduction abnormality requiring a pacemaker
•Valvular disease with documented compromise in cardiac function
•Symptomatic pericarditis
9.Patient has a history of cardiac dysfunction 10.Family history of congenital long or short QT, or known history of QT/QTc prolongation or Torsade de Point(TdP)
11.Inadequately controlled hypertension(i.e, SBP >180 mmHg or DBP >100mmHg)
12.Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea grade = 2, malabsorption syndrome, or small bowel resection)
13.Patient is concurrently using other approved antineoplastic or any investigational agents (hormonal agent included) in the last 30 days prior to start of treatment
14.Patient receiving chronic treatment with systemic steroids or another immunosuppressive agent at start of study treatment..
16.Patient is currently being treated with any of the following drugs:
•Moderate and strong inhibitors or inducers of CYP3A4/5 (Please refer to Appendix 1 for a list of prohibited CYP3A4 inhibitors and inducers)
•Drugs with known risk to induce Torsades de Pointes (see Appendix 3 for a list of prohibited drugs)
•Warfarin or coumarin analogues
•LHRH agonists
17.Patient is consuming Seville oranges, grapefruit, grapefruit hybrids, pummelos and exotic citrus fruits (as well as their juices) during the last 7 days prior to start of treatment. Regular orange juice is permitted
18.Immunocompromised patients, including known seropositivity for HIV (testing is not mandatory)
19.Patient has other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s jud

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials